Bend Research Enters Into Collaboration With Vertex

Bend Research has entered into a collaboration with Vertex Pharmaceuticals (Vertex). Through the collaboration, Vertex will utilise Bend’s formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.

Reportedly, the collaboration between Bend Research and Vertex is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimised for therapeutic benefit.

Rod Ray, CEO of Bend Research, said: “It’s a great opportunity for both companies. We are excited to be working with Vertex. We share their commitment to delivering breakthrough therapies based on cutting-edge science. Having two great teams working side by side is a powerful combination – we look forward to a long and fruitful relationship.”

Peter Mueller, executive vice president of global research and development and chief scientific officer at Vertex, said: “Our collaboration with Bend Research exemplifies Vertex’s commitment to the treatment of serious diseases through cutting-edge science and innovative technologies. We believe Bend’s technologies and expertise will provide Vertex with important scientific capabilities that will support our drug development efforts.”